Senator Angus S. King Jr. (I-Maine) recently sold shares of Thermo Fisher Scientific Inc. NYSE: TMO. In a filing disclosed on August 18th, the Senator disclosed that they had sold between $1,001 and $15,000 in Thermo Fisher Scientific stock on July 21st.
Senator Angus S. King Jr. also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of JPMorgan Chase & Co. NYSE: JPM on 7/21/2025.
- Purchased $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 7/21/2025.
- Purchased $1,001 - $15,000 in shares of Lowe's Companies NYSE: LOW on 7/21/2025.
- Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOGL on 7/21/2025.
- Purchased $1,001 - $15,000 in shares of Exxon Mobil NYSE: XOM on 7/21/2025.
- Purchased $1,001 - $15,000 in shares of Arista Networks NYSE: ANET on 7/21/2025.
- Purchased $1,001 - $15,000 in shares of Uber Technologies NYSE: UBER on 7/21/2025.
- Purchased $1,001 - $15,000 in shares of Netflix NASDAQ: NFLX on 7/21/2025.
- Purchased $1,001 - $15,000 in shares of PayPal NASDAQ: PYPL on 7/21/2025.
- Purchased $1,001 - $15,000 in shares of Quanta Services NYSE: PWR on 7/21/2025.
Thermo Fisher Scientific Price Performance
Shares of Thermo Fisher Scientific stock opened at $483.4280 on Friday. The stock has a market capitalization of $182.55 billion, a price-to-earnings ratio of 27.96, a P/E/G ratio of 2.64 and a beta of 0.74. The firm's 50-day moving average price is $441.06 and its two-hundred day moving average price is $458.02. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.Thermo Fisher Scientific's revenue was up 2.9% compared to the same quarter last year. During the same period in the previous year, the business earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.
Thermo Fisher Scientific Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.
Analyst Upgrades and Downgrades
A number of analysts recently weighed in on TMO shares. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Barclays boosted their target price on Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 24th. Royal Bank Of Canada decreased their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Robert W. Baird boosted their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. Finally, Raymond James Financial reaffirmed an "outperform" rating and issued a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, Thermo Fisher Scientific has an average rating of "Moderate Buy" and a consensus target price of $593.00.
Read Our Latest Report on TMO
Insider Transactions at Thermo Fisher Scientific
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $451.82, for a total value of $4,518,200.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares in the company, valued at $52,037,916.68. This represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 18,896 shares of company stock valued at $8,593,838. Insiders own 0.33% of the company's stock.
Institutional Trading of Thermo Fisher Scientific
Hedge funds have recently modified their holdings of the company. Norges Bank acquired a new position in Thermo Fisher Scientific during the second quarter valued at approximately $2,264,615,000. GAMMA Investing LLC boosted its position in shares of Thermo Fisher Scientific by 60,610.9% during the first quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock worth $1,203,859,000 after purchasing an additional 2,415,346 shares in the last quarter. Soundwatch Capital LLC acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at $807,713,000. T. Rowe Price Investment Management Inc. increased its position in shares of Thermo Fisher Scientific by 86.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock valued at $1,604,338,000 after buying an additional 1,433,444 shares in the last quarter. Finally, Flossbach Von Storch SE raised its stake in Thermo Fisher Scientific by 93.0% during the 2nd quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company's stock worth $1,105,698,000 after buying an additional 1,314,182 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.
About Senator King
Angus King (independent) is a member of the U.S. Senate from Maine. He assumed office on January 3, 2013. His current term ends on January 3, 2031.
King (independent) ran for re-election to the U.S. Senate to represent Maine. He won in the general election on November 5, 2024.
About Thermo Fisher Scientific
(
Get Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
MarketBeat All Access